Short duration response-guided treatment is effective for most individuals with recent hepatitis C infection: the ATAHC II and DARE-C I studies
Marianne Martinello, Margaret Hellard, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Barbara Yeung, Laurence Maire, David Iser, Andrew Lloyd, Alexander Thompson, Joe Sasadeusz, Paul Haber, Gregory J Dore, Gail V Matthews
Antiviral Therapy | INT MEDICAL PRESS LTD | Published : 2016
Awarded by National Institute on Drug Abuse of the National Institutes of Health
The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. The Burnet Institute receives funding from the Victorian Operational Infrastructure Support Program. Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under award R01DA015999 and Janssen-Cilag Pty Ltd. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. JG and GVM are supported through NHMRC Career Development Fellowships. GJD and AL are supported through NHMRC Practitioner Fellowships.